<scp>DOAC‐Remove</scp> to counteract the interference of <scp>anti‐Xa</scp> oral anticoagulants on the monitoring of heparin

Abstract Introduction The monitoring of unfractionated heparin (UFH) by anti‐factor Xa activity (AXA) is commonly used to ensure effective anticoagulation and prevent bleeding risk. However, in patients previously treated with an anti‐Xa direct oral anticoagulant (DOAC) switching to UFH therapy, there is a risk of interference that may lead to inappropriate anticoagulation. The first objective of this study was to validate DOAC‐Remove to remove DOAC for measuring UFH specific AXA. The second objective was to assess the length of DOAC interference on UFH monitoring and to identify potential predictive factors. Materials and Methods This monocentric retrospective study included all patients admitted from April 2019 to April 2021 previously treated with anti‐Xa DOAC, and for whom an interference on UFH monitoring was suspected. Interference was defined as a difference in the AXA measured before and after using DOAC‐Remove &gt;2.8‐fold standard deviation of the method. Results Removal with DOAC‐Remove was specific of DOAC (apixaban n = 42, rivaroxaban n = 41, UFH n = 20) and sufficient to avoid interference on UFH AXA measurement. The exact interference length was 6.0 days [IQR 3.0–11.0] for apixaban ( n = 26) and 4.5 days [IQR 2.0–5.8] for rivaroxaban ( n = 20). Among the 89 patients sorted based on an interference length ≤ or &gt;3 days, 74 (83.1%) presented an interference greater than 3 days. Correlations were observed with age for apixaban and creatinine for rivaroxaban. Conclusions Our results suggest that DOAC‐Remove could be of high interest in patients receiving UFH previously treated with an anti‐Xa DOAC even if DOAC was stopped for more than 3 days.